C. Bonithon-kopp et al., Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial, LANCET, 356(9238), 2000, pp. 1300-1306
Citations number
29
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background Some epidemiological studies have suggested that high dietary in
take of calcium and fibre reduces colorectal carcinogenesis. Available data
are not sufficient to serve as a basis for firm dietary advice. We underto
ok a multicentre randomised trial to test the effect of diet supplementatio
n with calcium and fibre on adenoma recurrence.
Methods We randomly assigned 665 patients with a history of colorectal aden
omas to three treatment groups, in a parallel design: calcium gluconolactat
e and carbonate (2 g elemental calcium daily), fibre (3.5 g ispaghula husk)
, or placebo. Participants had colonoscopy after 3 years of followup. The p
rimary endpoint was adenoma recurrence. Analyses were by intention to treat
.
Findings 23 patients died, 15 were lost to follow-up, 45 refused repeat col
onoscopy, and five developed severe contraindications to colonoscopy. Among
the 552 participants who completed the follow-up examination, 94 slopped t
reatment early. At least one adenoma developed in 28 (15.9%) of 176 patient
s in the calcium group, 58 (29.3%) of 198 in the fibre group, and 36 (20.2%
) of 178 in the placebo group. The adjusted odds ratio for recurrence was 0
.66 (95% CI 0.38-1.17. p=0.16) for calcium treatment and 1.67 (1.01-2.76, p
=0.042) for the fibre treatment. The odds ratio associated with the fibre t
reatment was significantly higher in participants with baseline dietary cal
cium intake above the median than in those with intake below the median (in
teraction test, p=0.028)
Interpretation Supplementation with fibre as ispaghula husk may have advers
e effects on colorectal adenoma recurrence, especially in patients with hig
h dietary calcium intake. Calcium supplementation was associated with a mod
est but not significant reduction in the risk of adenoma recurrence.